公眾如有相關醫學需求，請向醫療保健專業人士咨詢(如至社區衛生服務中心)，以獲得個人醫療建議。有效期至 2026 年2月，過期等同于作廢。

參考文獻

1.LU L, SUO L, LI J, et al. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China [J]. Hum Vaccin Immunother, 2018, 14(11): 2632-5.

2.TSAI TF, YAO CA, YU HS, et al. Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in Taiwan: a prospective observational study [J]. Int J Dermatol, 2015, 54(5): 529-36.

3.Steinmann M, L.D., Grosser J, Schmidt J, Hohoff ML, Fischer A, Greiner W, Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and

heterogeneity patterns. Infection, 2024. 52(3): p. 1009-1026.

4.Mu?oz-Quiles C, L.-L.M., Orrico-Sánchez A, Díez-Domingo J, Impact of postherpetic neuralgia: A six year population-based analysis on people aged 50 years or older. J Infect, 2018. 77: p. 131-136.

5.中國醫師協會皮膚科醫師分會帶狀皰疹專家共識工作組,國家皮膚與免疫疾病臨床醫學研究中心. 中國帶狀皰疹診療專家共識(2022版)[J]. 中華皮膚科雜志,2022,12:1033-1040.

6.MARRA F, PARHAR K, HUANG B, et al. Risk Factors for Herpes Zoster Infection: A Meta-Analysis [J]. Open Forum Infect Dis, 2020, 7(1): ofaa005.

7.Weinke T , Glogger A , Bertrand I ,et al.The Societal Impact of Herpes Zoster and Postherpetic Neuralgia on Patients, Life Partners, and Children of Patients in Germany[J].Scientificworldjournal, 2014.DOI:10.1155/2014/749698.

8.中國醫療保健國際交流促進會皮膚科分會. 帶狀皰疹疫苗預防接種專家共識[J]. 中華醫學雜志,2022,102(8):538-543.

9.WHO, Guidelines on clinical evaluation of vaccines: regulatory expectations.

https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9.2020.

10.WHO, Vaccine efficacy, effectiveness and protection.

https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection.2021.

*騰訊醫典內容團隊出品